McKesson Corporation
MCK · What the business does, what can go wrong, and how options sellers approach it
What it does
McKesson is one of the largest pharmaceutical distributors in the United States. It buys branded, generic and specialty medicines from drugmakers and delivers them to retail pharmacies, hospitals, clinics and other healthcare providers.
It also operates in Canada and offers technology and services to pharmacies and oncology practices.
How it makes money
McKesson earns a small margin on a very large volume of products moving through its network. Drugmakers sell to McKesson, and McKesson sells on to pharmacies and providers at a slightly higher price.
Other revenue comes from generic drug sourcing, specialty drug distribution, and fees for technology and services. Because margins per sale are thin, scale, logistics and purchasing power matter a great deal.
Why investors own it
Medicine demand tends to be steady in any economy, and an aging population generally uses more of it. Specialty drugs, such as those used in cancer care, are a growing part of the market.
The industry is concentrated among a few large distributors, which can support pricing discipline and negotiating strength. Investors also like that the company has historically returned cash through share buybacks and dividends, though neither is guaranteed.
What can go wrong
- Drug pricing reform or reimbursement changes could squeeze margins.
- Large customers can negotiate hard, and losing one would hurt.
- Generic drug price swings affect profits.
- Legal and regulatory risk is real, including litigation tied to opioid distribution.
- Thin margins leave little room for operational mistakes.
What to watch
- Operating profit by segment
- Specialty and oncology volume trends
- Generic drug pricing conditions
- Changes in major customer contracts
- Drug pricing and reimbursement policy
- Litigation and settlement developments
- Share repurchase activity and capital allocation
Options income angle
Options on MCK are generally available across multiple expirations and are usually reasonably liquid, though trading is thinner than in the most heavily traded large-cap names. Bid-ask spreads can be wider on strikes far from the current price.
Implied volatility tends to rise ahead of quarterly earnings and around news on drug pricing policy, regulation or litigation. It is often moderate outside those windows.
One caution for premium sellers: a defensive reputation does not prevent sharp single-day moves on earnings or policy headlines. A covered call can cap gains, and a cash-secured put can leave you owning shares after a sudden drop.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended March 31, 2026, filed May 8, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
McKesson's fiscal year ended March 31, 2026 brought revenues up 12% to $403,430 million and diluted earnings per share of $38.38, up from $25.72. The filing also shows a company reshaping itself: it plans to separate its Medical-Surgical Solutions segment, it bought two large physician-services businesses, and it carries a $5.7 billion opioid liability. One customer, CVS, accounts for about 24% of revenues.
How the business did
- Revenues were $403,430 million against $359,051 million. North American Pharmaceutical grew on higher volumes from retail national account customers. Oncology & Multispecialty revenues rose 31% on added practice-management providers and higher specialty drug sales.
- Net income attributable to McKesson was $4,762 million versus $3,295 million. The year included a $480 million net gain on selling the Norway businesses and a $210 million LIFO credit. LIFO is an inventory method, and it produces a credit when drug prices fall. Gains from antitrust settlements fell to $23 million from $444 million.
- Segment operating profit was $3,658 million in North American Pharmaceutical, $1,149 million in Oncology & Multispecialty, $1,044 million in Prescription Technology Solutions and $938 million in Medical-Surgical Solutions.
- Operating cash flow was $6,155 million. The company returned $5.1 billion to shareholders, made up of $4.8 billion of share repurchases and $381 million of dividends. It raised the quarterly dividend to $0.82 from $0.71.
Risks specific to this company
- Customer concentration: CVS accounted for about 24% of revenues and about 21% of trade receivables. The ten largest customers made up about 73% of revenues and about 43% of receivables.
- Opioid litigation: The accrued liability was $5.7 billion, with $601 million expected to be paid within twelve months and the rest in installments through 2038. Management says it cannot estimate the range of possible losses across all opioid matters.
- Planned separation of Medical-Surgical Solutions: Completion depends on conditions including a favorable tax opinion, a registration statement and board approval. The IRS or a court could also rule the transaction taxable.
- Change Healthcare tax exposure: If the 2020 split-off is found not to be tax-free, the company and participating stockholders could owe substantial federal income taxes. Change Healthcare's indemnity covers only certain situations.
- Drug pricing and reimbursement reform: The filing lists the IRA, the OBBBA, Executive Order 14297, 340B program litigation and state drug pricing laws. These could affect pricing and distribution economics.
- Supplier and customer consolidation: A few large suppliers control much of the pharmaceuticals market, which limits the company's ability to negotiate terms. Consolidated customers also have more pricing power, which could erode margins.
What management is watching
- Separation of Medical-Surgical Solutions: Apollo Funds agreed to invest approximately $1.25 billion in convertible preferred equity for approximately 13% of the segment. Segment subsidiaries also arranged a $750 million term loan due in 2031, a $250 million term loan due in 2028 and a $1.0 billion revolving credit facility. Separation charges were $77 million in the year.
- Oncology and multispecialty growth: The company paid $2.5 billion for a 70% interest in Core Ventures and $875 million for an 80% interest in PRISM Vision. Integration costs for the two were $96 million.
- Cost programs: An enterprise-wide initiative expects total charges of $650 million to $700 million, substantially complete in fiscal 2028. A new Prescription Technology Solutions initiative expects $200 million to $250 million, to be completed by the end of fiscal 2029.
- Capital return and liquidity: In April 2026 the board added $5.0 billion to the repurchase authorization, bringing it to $7.7 billion. A new $5.0 billion credit facility matures in April 2031.
- Measures cited: Management points to revenues and operating profit by segment, and to a debt to capital ratio of 128.0%. That ratio runs above 100% because the company has a stockholders' deficit. Fiscal 2027 outlook is in a separate earnings release, not in these sections.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 4, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
McKesson's revenues rose 8% to $110,957 million for the three months ended September 30, 2026, and diluted earnings per share rose to $10.44 from $8.92. Growth came mainly from drug distribution in North American Pharmaceutical and specialty drug sales in Oncology & Multispecialty. The quarter also brought heavy deal activity and costs tied to the planned separation of the Medical-Surgical Solutions business.
How the business did
- Quarter: Gross profit was $3,956 million, up 12% from $3,542 million. Net income attributable to McKesson was $1,218 million, up 10%. Over six months, revenues rose 8% to $216,337 million. Diluted EPS was $15.53 against $15.16, but net income attributable to McKesson fell 3% to $1,832 million. Net income attributable to noncontrolling interests (the share belonging to outside owners) was $496 million against $100 million, including charges of $282 million for Medical-Surgical Solutions and $109 million for Core Ventures to remeasure those interests.
- Segments: North American Pharmaceutical revenues were $91,360 million, up 6%, on higher volumes from institutional providers and retail national accounts, including GLP-1 drug demand, partly offset by branded price decreases and the shift to generics. Oncology & Multispecialty revenues were $14,980 million, up 24%. Medical-Surgical Solutions operating profit fell 25% to $164 million, on $42 million of separation charges and a weaker ambulatory care business.
- Unusual items: North American Pharmaceutical recorded gains of $50 million for the company's share of antitrust legal settlements. Interest expense rose to $105 million from $74 million, driven mainly by the MMS Credit Agreement.
- Cash and capital return: Six-month operating cash flow was $2,850 million against $1,502 million, which management partly ties to payment timing and the day of the week the period ended. The company returned $3.6 billion to shareholders: $3.4 billion of buybacks and $198 million of dividends. The quarterly dividend was raised from $0.82 to $0.94 per share, and weighted-average diluted shares fell to 116.7 million from 124.4 million.
What management is watching
- Deals and separation: Apollo Funds invested approximately $1.25 billion for about 13% of Medical-Surgical Solutions. In early November the company completed the Precision Medicine purchase (approximately $2.25 billion) and a controlling stake in Spectrum Vision (approximately $525 million). It also agreed to buy a 49% interest in Option Care Health for approximately $1.4 billion, expected to close in the first half of calendar year 2027.
- Restructuring: Three efficiency programs are under way, with expected total charges of approximately $230 million to $310 million (Corporate), $200 million to $250 million (Prescription Technology Solutions) and $650 million to $700 million (technology and operating model). The filing expects them to be substantially complete between fiscal 2028 and fiscal 2029.
- Capital and obligations: $4.3 billion of share repurchase authorization remained at September 30, 2026. Estimated opioid-related litigation liability was $5.2 billion. The debt to capital ratio was 152.9% against 128.0% at March 31, 2026.
- Policy: Management points to fast-changing government policy, including the federal 340B drug discount program and drug pricing, as hard to predict. The filing gives no earnings outlook.
Follow MCK in Kortex
The Kortex app shows MCK's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.